1 / 5

10% Discount on Mature Biotech ( Valid till 7th June 2016)

For more information kindly visit : https://www.bharatbook.com/biotechnology-market-research-reports-641519/mature-biotech-outlook-new-therapy-ventures-pave-way-success.html Bharat Book Bureau provides the report, on “ Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success ”. All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors.

bharatbookseo
Download Presentation

10% Discount on Mature Biotech ( Valid till 7th June 2016)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 10 % Discount on Mature Biotech (Valid till 7th June 2016)

  2. Summary All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche indication where the high treatment cost justifies the need. While large pharma companies are active in M&A deals, the Mature biotech companies are sticking to its core expertise and venturing into unexplored/new therapy; e.g., GILD in anti-cancer and BIIB for hemophilia. Alike small molecule generics, biosimilar will also get easier and getting similar pace of recognition in coming years; where AMGN, BIIB already started investing in this space and can emerge as a big player in coming years. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  poonam@bharatbook.com

  3. REGN, ALXN, and VRTX have transformed into a large-cap mature biotech companies. Whether these three will be acquired or will remain independent and evolve in next giant is still a question, but both the cases present a good investment opportunity for those who willing to hold them for next five years. GILD has announced the dividend payment and now all eyes will be on CELG and BIIB. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  poonam@bharatbook.com

  4. Table of Contents 1. Acorda Therapeutics – Neurological Pipeline Getting Bigger 2. Alexion Pharma – Pipeline Maturity will witness a Strong 2015 for ALXN 3. Amgen – Focus On New Biologics For Larger Market 4. Biogen Idec – Growth from Newly Launched Products 5. Celgene – Innovative Strategies for Long Term Gains 6. Gilead Sciences – Poised to Emerge as a Leader in HCV Treatment 7. Regeneron – Late-Stage Pipeline Potential W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  poonam@bharatbook.com

  5. To view the full Executive Summary and Table of Contents, please visit: 10 % Discount on Mature Biotech outlook Contact Us:-Call India: +91-22-27810772/73Email id : poonam@bharatbook.comWebsite : www.bharatbook.comOur Blog : https://www.bharatbook.com/blog/ W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  poonam@bharatbook.com

More Related